Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1 trials; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Competitive Edge | Delve into Arcellx's differentiation strategy, focusing on anito-cel's efficacy and safety advantages over rival therapies in the evolving CAR-T landscape |
Financial Outlook | Analysts project sales growth from $110.3M in 2023 to $119.1M in 2024, with an average price target of $115, reflecting confidence in Arcellx's market position |
Market Dynamics | Explore the shifting landscape of multiple myeloma treatment, with CAR-T therapies projected to capture 30% of the market, presenting significant growth potential |
CAR-T Breakthrough | Arcellx's anito-cel shows promise in multiple myeloma treatment, with a 97% overall response rate and superior safety profile in clinical trials |
Metrics to compare | ACLX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipACLXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −18.3x | −1.6x | −0.6x | |
PEG Ratio | 0.04 | 0.03 | 0.00 | |
Price / Book | 9.1x | 1.2x | 2.6x | |
Price / LTM Sales | 111.1x | 9.6x | 3.4x | |
Upside (Analyst Target) | 64.1% | 618.4% | 44.4% | |
Fair Value Upside | Unlock | 13.2% | 6.1% | Unlock |